Research Topics
| KARL D KIEBURTZSummaryAffiliation: University of Rochester Country: USA Publications
Research Grants
| Collaborators
|
Detail Information
Publications
Discovering neuroprotection in Parkinson's disease, or getting to haphazardKarl Kieburtz
University of Rochester Medical Center, Rochester, NY, USA
Mt Sinai J Med 77:700-6. 2010..Any possible insights will require confirmation in rigorous clinical trial testing. Combining the useful insights from all perspectives may be the most promising approach to discovering a neuroprotective therapy...- Twice-daily, low-dose pramipexole in early Parkinson's disease: a randomized, placebo-controlled trialKarl Kieburtz
University of Rochester Medical Center, Rochester, New York 14620, USA
Mov Disord 26:37-44. 2011..In this fixed dosage, randomized study pramipexole administered twice daily at a total daily dosage of 1.0-1.5 mg daily was of comparable efficacy and tolerability to a dosage of 0.5 mg tid over a 12-week treatment period in early PD... - Therapeutic strategies to prevent motor complications in Parkinson's diseaseKarl Kieburtz
University of Rochester Medical Center, 1351 Mt Hope Ave, Ste 223, Rochester, NY 14620, USA
J Neurol 255:42-5. 2008..These data have led to evidence-based medicine evaluations indicating that the use of dopamine agonists is efficacious and clinically useful for the prevention of motor complications... 
Translational experimental therapeutics: The translation of laboratory-based discovery into disease-related therapyKarl Kieburtz
Neurology Department, University of Rochester Medical Center, Rochester, New York 14620, USA
Mt Sinai J Med 74:7-14. 2007....- Issues in neuroprotection clinical trials in Parkinson's diseaseKarl Kieburtz
University of Rochester Medical Center, Rochester, New York, USA
Neurology 66:S50-7. 2006..Improved clinical trial design along with continued new insights into PD pathogenesis will likely lead to the identification of agents which can favorably influence the course of this disease... - Why hasn't neuroprotection worked in Parkinson's disease?Karl Kieburtz
University of Rochester Medical Center, Rochester, NY, USA
Nat Clin Pract Neurol 3:240-1. 2007 - Cancer incidence in a trial of an antiapoptotic agent for Parkinson's diseaseSteven R Schwid
Department of Neurology, University of Rochester, Rochester, New York, USA
Mov Disord 25:1801-8. 2010..Melanoma occurrence in our PD patients was greater than predicted compared with the general population and was unrelated to dopaminergic therapy. Clinical surveillance of PD patients for melanoma may be warranted... - Levodopa and the progression of Parkinson's diseaseStanley Fahn
Columbia University, New York, USA
N Engl J Med 351:2498-508. 2004..This study assessed the effect of levodopa on the rate of progression of Parkinson's disease... - The relationship between CAG repeat length and clinical progression in Huntington's diseaseBernard Ravina
Department of Neurology, University of Rochester School of Medicine and Dentistry, Rochester, New York, USA
Mov Disord 23:1223-7. 2008..This finding may account for the variable results from previous studies examining CAGn and progression. Adjusting for CAGn may be important for clinical trials... 
Long term understanding of study information in research participants with Parkinson's diseaseBernard Ravina
University of Rochester, School of Medicine and Dentistry, Department of Neurology, Rochester, NY 14610, USA
Parkinsonism Relat Disord 16:60-3. 2010..Little is known about research participants' understanding of consent information over the course of a clinical study and the relationship of this information with participant behavior...- A longitudinal program for biomarker development in Parkinson's disease: a feasibility studyBernard Ravina
Department of Neurology, University of Rochester School of Medicine and Dentistry, Rochester, New York, USA
Mov Disord 24:2081-90. 2009..The PostCEPT cohort and associated studies strongly support the feasibility of the LABS-PD approach of retaining and repurposing clinical trial cohorts to collect longitudinal clinical and biomarker data... - A randomized, placebo-controlled trial of oxycodone and of gabapentin for acute pain in herpes zosterRobert H Dworkin
Department of Anesthesiology, University of Rochester School of Medicine and Dentistry, 601 Elmwood Avenue, Box 604, Rochester, NY 14642, USA
Pain 142:209-17. 2009.... - The relationship between uric acid levels and Huntington's disease progressionPeggy Auinger
Department of Neurology, University of Rochester School of Medicine and Dentistry, Rochester, New York 14620, USA
Mov Disord 25:224-8. 2010..If confirmed, UA could be an important predictor and potentially modifiable factor affecting the rate of HD progression... - Motor abnormalities in premanifest persons with Huntington's disease: the PREDICT-HD studyKevin M Biglan
University of Rochester, Rochester, New York, USA
Mov Disord 24:1763-72. 2009..Longitudinal assessment will help inform whether motor items will be useful measures in preventive clinical trials... - Fatigue in levodopa-naive subjects with Parkinson diseaseG Schifitto
University of Rochester, NY, USA
Neurology 71:481-5. 2008..Fatigue is a common complaint in Parkinson disease (PD). We investigated fatigue in a cohort of previously untreated patients with early PD enrolled in the Earlier vs Later Levodopa (ELLDOPA) clinical trial... - Impact of sustained deprenyl (selegiline) in levodopa-treated Parkinson's disease: a randomized placebo-controlled extension of the deprenyl and tocopherol antioxidative therapy of parkinsonism trialIra Shoulson
University of Rochester Medical Center, Rochester, NY 14620, USA
Ann Neurol 51:604-12. 2002.... - Needed in MS: evidence, not EVIDENCEKarl Kieburtz
Department of Neurology, University of Rochester Medical Center, NY 14642, USA
Neurology 59:1482-3. 2002 - Gabapentin's effects on hot flashes in postmenopausal women: a randomized controlled trialThomas Guttuso
Department of Neurology, University of Rochester, Rochester, New York 14642, USA
Obstet Gynecol 101:337-45. 2003..To evaluate whether treatment with the anticonvulsant gabapentin may be effective in reducing hot flash frequency and severity... - Designing neuroprotection trials in Parkinson's diseaseKarl Kieburtz
University of Rochester Medical Center, Rochester, NY 14620, USA
Ann Neurol 53:S100-7; discussion S107-9. 2003.... - Pramipexole vs levodopa as initial treatment for Parkinson disease: a 4-year randomized controlled trialRobert G Holloway
Department of Neurology, University of Rochester, 1351 Mt Hope Avenue, Suite 220, Rochester, NY 14620, USA
Arch Neurol 61:1044-53. 2004..The best way to initiate dopaminergic therapy for early Parkinson disease remains unclear... - TCH346 as a neuroprotective drug in Parkinson's disease: a double-blind, randomised, controlled trialC Warren Olanow
Department of Neurology and Neuroscience, Mount Sinai School of Medicine, New York, NY 10029, USA
Lancet Neurol 5:1013-20. 2006..TCH346 is a potent anti-apoptotic drug that protects against loss of dopaminergic neurons in laboratory models. Our aim was to assess TCH346 as a neuroprotective drug in patients with Parkinson's disease... - Malignant melanoma in early Parkinson's disease: the DATATOP trialRadu Constantinescu
Department of Neurology, University of Rochester Medical Center, Rochester, NY 14620, USA
Mov Disord 22:720-2. 2007..The standardized event ratio was 3.3 (95% confidence interval, 1.1-7.8), indicating that incidence of malignant melanoma was higher than expected. We found no association between levodopa therapy and the incidence of melanoma... - Impact of pramipexole on the onset of levodopa-related dyskinesiasRadu Constantinescu
Department of Neurology, University of Rochester Medical Center, Rochester, New York, USA
Mov Disord 22:1317-9. 2007.... - A randomized study of the bioavailability of different formulations of coenzyme Q(10) (ubiquinone)Radu Constantinescu
Department of Neurology, Clinical Trials Coordination Center, University of Rochester Medical Center, Rochester, New York, USA
J Clin Pharmacol 47:1580-6. 2007 - An evaluation of neurocognitive status and markers of immune activation as predictors of time to death in advanced HIV infectionJeffrey J Sevigny
Department of Neurology and Gertrude H Sergievsky Center, College of Physicians and Surgeons, Columbia University, New York, NY, USA
Arch Neurol 64:97-102. 2007..Several markers of immune activation have been identified as potential prognostic markers for human immunodeficiency virus (HIV)-associated morbidity and mortality, but the results from studies are conflicting... - Why have we failed to achieve neuroprotection in Parkinson's disease?C Warren Olanow
Department of Neurology, Mount Sinai School of Medicine, New York, USA
Ann Neurol 64:S101-10. 2008..New developments in understanding the cause of the disease, in the development of animal models of PD, and in clinical trial methodology will hopefully hasten the resolution of these problems... - Dietary intake in adults at risk for Huntington disease: analysis of PHAROS research participantsK Marder
Departments of Neurology and Psychiatry, Taub Institute for Research on Alzheimer s Disease and the Aging Brain, Gertrude H Sergievsky Center, Columbia University, New York, NY 10032, USA
Neurology 73:385-92. 2009..To examine caloric intake, dietary composition, and body mass index (BMI) in participants in the Prospective Huntington At Risk Observational Study (PHAROS)... - Defining disease-modifying therapies for PD--a road map for moving forwardC Warren Olanow
Department of Neurology and Neuroscience, Mount Sinai School of Medicine, New York, New York 10029, USA
Mov Disord 25:1774-9. 2010..Together these two trials provide a road map for defining a disease modifying drug and determining the long term cumulative effect of the drug on the disease... - Pivotal studies of orphan drugs approved for neurological diseasesJun Mitsumoto
College of Physicians and Surgeons, Columbia University, New York, NY, USA
Ann Neurol 66:184-90. 2009..To identify design elements of clinical trials leading to US Food and Drug Administration approval of drugs for neurological diseases with and without orphan indications...
Research Grants
- MIDCAREER INVESTIGATOR AWARD--PATIENT ORIENTED RESEARCHKarl Kieburtz; Fiscal Year: 2003..abstract_text> ..
- Neuroprotection Studies in PD: A Coordinating CenterKarl Kieburtz; Fiscal Year: 2007..An appropriate research infrastructure combined with relevant scientific expertise is in place to conduct the proposed studies of neuroprotective agents in PD. ..